

# Enrico Franceschi

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2075338/enrico-franceschi-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

148  
papers

5,553  
citations

34  
h-index

72  
g-index

181  
ext. papers

6,540  
ext. citations

4.5  
avg, IF

5.19  
L-index

#	Paper	IF	Citations
148	Molecular Targeted Therapies: Time for a Paradigm Shift in Medulloblastoma Treatment?. <i>Cancers</i> , <b>2022</b> , 14,	6.6	1
147	Glioblastoma Microenvironment: From an Inviolable Defense to a Therapeutic Chance.. <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 852950	5.3	4
146	Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?. <i>Drugs</i> , <b>2022</b> , 82, 491	12.1	2
145	Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene Panel. <i>Diagnostics</i> , <b>2022</b> , 12, 1058	3.8	0
144	Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem. <i>Expert Review of Anticancer Therapy</i> , <b>2021</b> , 21, 1333-1353	3.5	4
143	Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis. <i>Advances in Therapy</i> , <b>2021</b> , 1	4.1	2
142	BET inhibitors: the promise of a new generation of immunotherapy in glioblastoma. <i>Immunotherapy</i> , <b>2021</b> ,	3.8	2
141	Discovering the Molecular Landscape of Meningioma: The Struggle to Find New Therapeutic Targets. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	2
140	Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. <i>Immunotherapy</i> , <b>2021</b> , 13, 419-432	3.8	3
139	Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma. <i>European Journal of Cancer</i> , <b>2021</b> , 147, 1-12	7.5	2
138	Expertise is crucial to prolong survival in average risk medulloblastoma: long-term results of a retrospective study. <i>Tumori</i> , <b>2021</b> , 3008916211017213	1.7	0
137	IDH1 single nucleotide polymorphism improves progression free survival in patients with IDH mutated grade II and III gliomas. <i>Pathology Research and Practice</i> , <b>2021</b> , 221, 153445	3.4	2
136	The clinical and prognostic role of ALK in glioblastoma. <i>Pathology Research and Practice</i> , <b>2021</b> , 221, 153447	3.4	1
135	IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment. <i>Molecular Diagnosis and Therapy</i> , <b>2021</b> , 25, 457-473	4.5	3
134	Molecular alterations in pancreatic tumors. <i>World Journal of Gastroenterology</i> , <b>2021</b> , 27, 2710-2726	5.6	4
133	Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives. <i>Oncologist</i> , <b>2021</b> , 26, 865-878	5.7	7
132	Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas. <i>CNS Oncology</i> , <b>2021</b> , 10, CNS72	4	6

131	Glioblastoma: Emerging Treatments and Novel Trial Designs. <i>Cancers</i> , <b>2021</b> , 13,	6.6	5
130	Development of Randomized Trials in Adults with Medulloblastoma-The Example of EORTC 1634-BTG/NOA-23. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
129	IDH1 Non-Canonical Mutations and Survival in Patients with Glioma. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	6
128	Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study. <i>European Journal of Cancer</i> , <b>2021</b> , 145, 171-178	7.5	3
127	Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer?. <i>Clinical Drug Investigation</i> , <b>2021</b> , 41, 757-773	3.2	0
126	Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review. <i>Clinical Case Reports (discontinued)</i> , <b>2021</b> , 9, e04604	0.7	0
125	Immune-checkpoint inhibitors in pituitary malignancies. <i>Anti-Cancer Drugs</i> , <b>2021</b> , 33,	2.4	1
124	Radiomics, mirnomics, and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light. <i>Expert Review of Anticancer Therapy</i> , <b>2021</b> , 21, 1265-1272	3.5	1
123	Next-Generation Sequencing Panel for 1p/19q Codeletion and IDH1-IDH2 Mutational Analysis Uncovers Mistaken Overdiagnoses of 1p/19q Codeletion by FISH. <i>Journal of Molecular Diagnostics</i> , <b>2021</b> , 23, 1185-1194	5.1	0
122	Is There a Role for Surgical Resection of Multifocal Glioblastoma? A Retrospective Analysis of 100 Patients. <i>Neurosurgery</i> , <b>2021</b> , 89, 1042-1051	3.2	0
121	Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. <i>Lancet Oncology</i> , <b>2020</b> , 21, e317-329	21.7	31
120	miR-196B-5P and miR-200B-3P Are Differentially Expressed in Medulloblastomas of Adults and Children. <i>Diagnostics</i> , <b>2020</b> , 10,	3.8	4
119	Predictive markers of immune response in glioblastoma: hopes and facts. <i>Future Oncology</i> , <b>2020</b> , 16, 1053-1063	3.6	10
118	Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy. <i>Future Oncology</i> , <b>2020</b> , 16, 1433-1439	3.6	8
117	Neuro-Oncology During the COVID-19 Outbreak: A Hopeful Perspective at the End of the Italian Crisis. <i>Frontiers in Medicine</i> , <b>2020</b> , 7, 594610	4.9	5
116	EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand. <i>Neuro-Oncology Advances</i> , <b>2020</b> , 2, vdz051	0.9	6
115	INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 684-693	1.693	62
114	Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas. <i>European Journal of Cancer</i> , <b>2020</b> , 137, 10-17	7.5	9

113	Glioneuronal tumors: clinicopathological findings and treatment options. <i>Future Neurology</i> , <b>2020</b> , 15, FNL47	1.5	2
112	Rare Primary Central Nervous System Tumors in Adults: An Overview. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 996	5.3	4
111	Adjuvant chemotherapy in average-risk adult medulloblastoma patients improves survival: a long term study. <i>BMC Cancer</i> , <b>2020</b> , 20, 755	4.8	7
110	Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. <i>Expert Review of Anticancer Therapy</i> , <b>2020</b> , 20, 785-795	3.5	13
109	Concordance between RTOG and EORTC prognostic criteria in low-grade gliomas. <i>Future Oncology</i> , <b>2019</b> , 15, 2595-2601	3.6	3
108	Defining EGFR amplification status for clinical trial inclusion. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 1263-1272	1	12
107	Medulloblastoma and central nervous system germ cell tumors in adults: is pediatric experience applicable?. <i>Childs Nervous System</i> , <b>2019</b> , 35, 2279-2287	1.7	3
106	Survival outcomes in glioma patients with noncanonical IDH mutations: Beyond diagnostic improvements.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2028-2028	2.2	1
105	Adjuvant chemotherapy to improve survival in average-risk adult medulloblastoma patients: Long-term results.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2037-2037	2.2	1
104	Effect of grade on survival in IDH-mutant grade II and grade III gliomas.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2036-2036	2.2	
103	IDH1 polymorphism G105G (rs11554137) as a prognostic factor in gliomas.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e14734-e14734	2.2	
102	Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?. <i>Oncologist</i> , <b>2019</b> , 24, 664-670	5.7	2
101	EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, e715-e728	21.7	31
100	A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. <i>Oncologist</i> , <b>2019</b> , 24, 521-528	5.7	28
99	Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?. <i>Journal of Neuro-Oncology</i> , <b>2018</b> , 139, 383-388	4.8	9
98	The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power. <i>World Neurosurgery</i> , <b>2018</b> , 112, e342-e347	2.1	26
97	The burden of oncology promises not kept in glioblastoma. <i>Future Neurology</i> , <b>2018</b> , 13, 1-4	1.5	3
96	Prevalence of the single-nucleotide polymorphism rs11554137 (IDH1) in brain tumors of a cohort of Italian patients. <i>Scientific Reports</i> , <b>2018</b> , 8, 4459	4.9	5

95	The Risk Assessment in Low-Grade Gliomas: An Analysis of the European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) criteria. <i>Oncology and Therapy</i> , <b>2018</b> , 6, 105-108	2.7	4
94	Temozolomide rechallenge in recurrent glioblastoma: when is it useful?. <i>Future Oncology</i> , <b>2018</b> , 14, 1063-1069	3.1	7
93	Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2023-2023	2.2	10
92	Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2047-2047	2.2	3
91	Concordance between RTOG and EORTC risk factors in low grade gliomas: Who will remain standing in the ring at bell sound?. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2040-2040	2.2	
90	Third-line therapy in glioblastoma: Analysis of a single centre database.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e14057-e14057	2.2	
89	The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival?. <i>Future Oncology</i> , <b>2018</b> , 14, 1559-1567	3.6	15
88	Role of Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications. <i>Oncologist</i> , <b>2017</b> , 22, 432-437	5.7	43
87	Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1027-1037	59.2	525
86	Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria. <i>Journal of Neuro-Oncology</i> , <b>2017</b> , 135, 245-254	4.8	16
85	Immunotherapy in head and neck cancer: evidence and perspectives. <i>Immunotherapy</i> , <b>2017</b> , 9, 1351-1358	3.8	13
84	Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts. <i>CNS Drugs</i> , <b>2017</b> , 31, 675-684	6.7	19
83	Low grade glioma patients with IDH mutation and 1p19q codeletion: To treat or not to treat?. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2017-2017	2.2	3
82	Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study. <i>Oncotarget</i> , <b>2017</b> , 8, 55575-55581	3.3	9
81	The role of gender in glioblastoma: does it matter?. <i>Future Neurology</i> , <b>2016</b> , 11, 197-199	1.5	1
80	Nitrosoureas in the Management of Malignant Gliomas. <i>Current Neurology and Neuroscience Reports</i> , <b>2016</b> , 16, 13	6.6	32
79	Patient outcomes following second surgery for recurrent glioblastoma. <i>Future Oncology</i> , <b>2016</b> , 12, 1039-1044	3.4	21
78	Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study. <i>Journal of Neuro-Oncology</i> , <b>2016</b> , 128, 157-162	4.8	21

77	Adjuvant chemotherapy in adult medulloblastoma: is it an option for average-risk patients?. <i>Journal of Neuro-Oncology</i> , <b>2016</b> , 128, 235-40	4.8	30
76	Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <i>Cancer Chemotherapy and Pharmacology</i> , <b>2016</b> , 77, 115-20	3.5	22
75	A Randomized Controlled Trial of Tong Len Meditation Practice in Cancer Patients: Evaluation of a Distant Psychological Healing Effect. <i>Explore: the Journal of Science and Healing</i> , <b>2016</b> , 12, 42-9	1.4	3
74	A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, LBA2-LBA2	2.2	24
73	Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma. <i>Oncotarget</i> , <b>2016</b> , 7, 55169-55180	3.3	31
72	The role of clinical characteristics and molecular biomarkers in low grade gliomas (LGG): A GICNO study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2032-2032	2.2	
71	AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 1304-12	1	53
70	Adult medulloblastoma <b>2016</b> , 582-584		
69	Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences. <i>Current Treatment Options in Oncology</i> , <b>2016</b> , 17, 49	5.4	37
68	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. <i>Lancet Oncology</i> , <b>2015</b> , 16, e534-e542	21.7	425
67	Bevacizumab in recurrent glioblastoma: open issues. <i>Future Oncology</i> , <b>2015</b> , 11, 2655-2665	3.6	9
66	Contribution of microRNA analysis to characterisation of pancreatic lesions: a review. <i>Journal of Clinical Pathology</i> , <b>2015</b> , 68, 859-69	3.9	16
65	Post progression survival in glioblastoma: where are we?. <i>Journal of Neuro-Oncology</i> , <b>2015</b> , 121, 399-404	4.8	8
64	New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 94, 348-59	7	35
63	Practical management of bevacizumab-related toxicities in glioblastoma. <i>Oncologist</i> , <b>2015</b> , 20, 166-75	5.7	42
62	Time to response (TTR) and early tumor shrinkage (ETS) in recurrent glioblastoma patients treated with bevacizumab: an exploratory analysis of the prospective randomized AVAREG (ML25739) phase II study.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2047-2047	2.2	1
61	The effect of re-operation on survival in patients with recurrent glioblastoma. <i>Anticancer Research</i> , <b>2015</b> , 35, 1743-8	2.3	35
60	The metastatic process: a kaleidoscope of concepts. <i>Future Oncology</i> , <b>2014</b> , 10, 697-8	3.6	2

59	Shedding light on adult medulloblastoma: current management and opportunities for advances. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014</i> , e82-7	7.1	13
58	The role of systemic and targeted therapies in brain metastases. <i>Expert Review of Anticancer Therapy, 2014</i> , 14, 93-103	3.5	6
57	Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-volume center?. <i>Neuro-Oncology Practice, 2014</i> , 1, 166-171	2.2	19
56	Resistance to antiangiogenic therapies. <i>Future Oncology, 2014</i> , 10, 1417-25	3.6	9
55	Final outcome results of platinum-sensitive small cell lung cancer (SCLC) patients treated with platinum-based chemotherapy rechallenge: A multi-institutional retrospective analysis.. <i>Journal of Clinical Oncology, 2014</i> , 32, 7600-7600	2.2	1
54	Association of high volume center with survival for glioblastoma patients: Results from a prospective population-based registry (PERNO).. <i>Journal of Clinical Oncology, 2014</i> , 32, 2048-2048	2.2	
53	Can average-risk medulloblastoma adult patients be treated with radiotherapy and plus chemotherapy?. <i>Journal of Clinical Oncology, 2014</i> , 32, 2022-2022	2.2	
52	Second surgery for recurrent glioblastoma: advantages and pitfalls. <i>Expert Review of Anticancer Therapy, 2013</i> , 13, 583-7	3.5	20
51	Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts. <i>Future Oncology, 2013</i> , 9, 1653-64	3.6	7
50	Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial. <i>European Journal of Cancer, 2013</i> , 49, 3609-15	7.5	64
49	Final results from a large prospective Italian population study on glioblastoma and correlations with MGMT status: The Project of Emilia-Romagna Region in Neuro-oncology (PERNO).. <i>Journal of Clinical Oncology, 2013</i> , 31, 2048-2048	2.2	
48	A large prospective Italian population study (Project of Emilia-Romagna Region in Neuro-Oncology; PERNO) in newly diagnosed GBM patients (pts): Outcome analysis and correlations with MGMT methylation status in the elderly population.. <i>Journal of Clinical Oncology, 2013</i> , 31, 2021-2021	2.2	
47	EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. <i>Neuro-Oncology, 2012</i> , 14, 1503-10	1	45
46	Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma. <i>European Journal of Cancer, 2012</i> , 48, 896-903	7.5	18
45	EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy, 2012</i> , 12, 1429-35	3.5	32
44	Cytologically confirmed splenic metastases in breast cancer. <i>Future Oncology, 2012</i> , 8, 1495-500	3.6	2
43	Anaplastic gliomas at first recurrence: Outcome analysis.. <i>Journal of Clinical Oncology, 2012</i> , 30, 2061-2061	2.2	1
42	Maintenance sunitinib (MS) or observation (O) in metastatic pancreatic adenocarcinoma (MPA): Clinical and translational results of a phase II randomized trial (NCT00967603).. <i>Journal of Clinical Oncology, 2012</i> , 30, 4017-4017	2.2	2

41	Natural history of glioblastoma in the modern era: Longitudinal results from a large prospective Italian register.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2057-2057	2.2	
40	Medulloblastomas in adults: prognostic factors and lessons from paediatrics. <i>Current Opinion in Neurology</i> , <b>2011</b> , 24, 626-32	7.1	15
39	Primary brain tumors in the elderly population. <i>Current Treatment Options in Neurology</i> , <b>2011</b> , 13, 427-35	4.4	6
38	End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era. <i>Expert Review of Anticancer Therapy</i> , <b>2011</b> , 11, 1713-7	3.5	2
37	New agents and new end points for recurrent gliomas. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, e245-6; author reply e247	2.2	5
36	Medulloblastomas <b>2011</b> , 415-433		
35	O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. <i>Neuro-Oncology</i> , <b>2010</b> , 12, 283-8	1	99
34	Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. <i>Oncologist</i> , <b>2010</b> , 15, 683-94	5.7	32
33	Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls. <i>Expert Review of Anticancer Therapy</i> , <b>2010</b> , 10, 179-84	3.5	10
32	Gangliogliomas: recent advances in classification and treatment. <i>Future Neurology</i> , <b>2010</b> , 5, 557-568	1.5	2
31	Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference. <i>BMC Cancer</i> , <b>2010</b> , 10, 48	4.8	27
30	Treatment options for recurrent glioblastoma: pitfalls and future trends. <i>Expert Review of Anticancer Therapy</i> , <b>2009</b> , 9, 613-9	3.5	29
29	Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. <i>Cancer</i> , <b>2009</b> , 115, 3512-8	6.4	179
28	Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 64, 769-75	3.5	75
27	Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET). <i>Critical Reviews in Oncology/Hematology</i> , <b>2009</b> , 71, 165-79	7	47
26	Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1275-9	2.2	249
25	Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 957-60	12.9	110
24	Association between response to primary treatments and MGMT status in glioblastoma. <i>Expert Review of Anticancer Therapy</i> , <b>2008</b> , 8, 1781-6	3.5	5



23	MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 2192-7	2.2	641
22	Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. <i>Neuro-Oncology</i> , <b>2008</b> , 10, 361-7	1	188
21	Chemotherapy in breast cancer patients with brain metastases: have new chemotherapeutic agents changed the clinical outcome?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2008</b> , 68, 212-21	7	27
20	Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. <i>Journal of Neuro-Oncology</i> , <b>2008</b> , 89, 179-85	4.8	73
19	Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2008</b> , 453, 599-609	5.1	53
18	Glioblastoma in adults. <i>Critical Reviews in Oncology/Hematology</i> , <b>2008</b> , 67, 139-52	7	126
17	Long-term results of a prospective study on the treatment of medulloblastoma in adults. <i>Cancer</i> , <b>2007</b> , 110, 2035-41	6.4	98
16	Prognostic factors for anaplastic astrocytomas. <i>Journal of Neuro-Oncology</i> , <b>2007</b> , 81, 295-303	4.8	29
15	Temozolomide as salvage treatment in primary brain lymphomas. <i>British Journal of Cancer</i> , <b>2007</b> , 96, 864-7	8.7	118
14	Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <i>British Journal of Cancer</i> , <b>2007</b> , 96, 1047-51	8.7	156
13	Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 4746-53	2.2	156
12	Is protracted low-dose temozolomide feasible in glioma patients?. <i>Neurology</i> , <b>2006</b> , 66, 427-9	6.5	39
11	Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). <i>British Journal of Cancer</i> , <b>2006</b> , 95, 1155-60	8.7	193
10	Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors. <i>Journal of Neuro-Oncology</i> , <b>2006</b> , 79, 299-305	4.8	13
9	High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. <i>Cancer</i> , <b>2005</b> , 103, 2344-8	6.4	188
8	A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia. <i>Cancer</i> , <b>2005</b> , 104, 143-8	6.4	64
7	Salvage temozolomide for prior temozolomide responders. <i>Cancer</i> , <b>2005</b> , 104, 2473-6	6.4	69
6	Temozolomide-induced partial response in a patient with primary diffuse leptomeningeal gliomatosis. <i>Journal of Neuro-Oncology</i> , <b>2005</b> , 73, 261-4	4.8	29

5	Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. <i>British Journal of Cancer</i> , <b>2004</b> , 90, 36-40	8.7	52
4	Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. <i>British Journal of Cancer</i> , <b>2004</b> , 91, 1038-44	8.7	45
3	Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. <i>European Journal of Cancer</i> , <b>2004</b> , 40, 1682-8	7.5	99
2	Gliomatosis cerebri: clinical, neurochemical and neuroradiological response to temozolomide administration. <i>Magnetic Resonance Imaging</i> , <b>2003</b> , 21, 1003-7	3.3	20
1	HER-2 Inhibitors: Clinical Results. <i>Tumori</i> , <b>2002</b> , 1, S3-S4	1.7	2